Price T Rowe Associates Inc T Scan Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 15,479 shares of TCRX stock, worth $25,075. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,479
Previous 12,301
25.84%
Holding current value
$25,075
Previous $62,000
22.58%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TCRX
# of Institutions
90Shares Held
41.1MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR5.36MShares$8.68 Million6.28% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5MShares$8.1 Million0.71% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$7.23 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.5MShares$5.67 Million0.02% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$4.84 Million0.34% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $30.7M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...